Sava Raises $36 Million in Series B Round
Sava, a health technology company based in London, has successfully raised $36 million in a Series B funding round. The round was led by Ascensia, with participation from Balderton Capital, Pentland Ventures, Norrsken VC, Simplyhealth Ventures, and JamJar Investments. Co-founders Rafaël Michali and Renato Circi are steering the company towards redefining personal health monitoring through its advanced wearable biosensor technology.
Wearable Biosensor Technology
Sava is pioneering the development of wearable biosensors that enable users to access vital health information in real-time. These devices are designed to be painless and affordable, providing a non-invasive alternative to traditional health monitoring methods. By focusing on the data just beneath the skin, Sava aims to transform how individuals interact with their health data.
Strategic Use of Funds
The newly acquired funds are expected to bolster Sava's efforts in expanding its product offerings and enhancing its technology. While specific plans were not disclosed, such funding typically supports scaling operations, product development, and market expansion.
Investor Confidence
The involvement of leading investors such as Ascensia and Balderton Capital underscores the confidence in Sava's innovative approach and its potential impact on the healthcare industry. This investment is a significant step forward for Sava as it continues to develop its groundbreaking biosensor technology.
Leadership Insights
Speaking about the funding, co-founder Rafaël Michali highlighted the importance of this investment in advancing their mission to make health monitoring more accessible and efficient. "Our goal is to empower individuals with real-time health insights that are both meaningful and actionable," Michali stated.
By securing this substantial investment, Sava is well-positioned to further its mission of transforming health monitoring through cutting-edge technology.